Efficacy of ceftazidime/avibactam versus other antimicrobial agents for treating multidrug- resistant <i>Pseudomonas aeruginosa</i>: a propensity-matched retrospective analysis.

ABSTRACT:

Introduction

Multidrug-resistant Pseudomonas aeruginosa (MDRPA) is a life-threatening infection with limited treatment options. As a novel combination drug of cephalosporin and beta-lactamase inhibitor, ceftazidime/avibactam (CAZ/AVI) is not much used in clinical treatment of MDRPA infections. To fill in this knowledge gap, a single-center real-world study was conducted.

Methods

This single-center retrospective observational study included MDRPA-infected patients treated with CAZ/AVI or other antimicrobial agents between January 2019 and April 2021. Propensity score-matched and binary logistic regression analysis was used to compare the clinical and microbiological efficacy between CAZ/AVI and other antimicrobial agents.

Results

Totally 363 patients with MDRPA

SUBMITTER: Qian Q 

PROVIDER: S-EPMC12738922 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature